Table 2 Baseline characteristics of neoadjuvant chemotherapy patients before and after PSM
Characteristics | Before PSM (N = 185) | After PSM (N = 86) | ||||
|---|---|---|---|---|---|---|
PLD group (N = 65) | Epirubicin group (N = 130) | P value | PLD group (N = 43) | Epirubicin group (N = 43) | P value | |
Age (year), n (%) | Â | Â | 0.0353 | Â | Â | 1.0000 |
  < 35 | 15 (23.1%) | 15 (11.5%) |  | 10 (23.3%) | 10 (23.3%) |  |
  ≥ 35 | 50 (76.9%) | 115 (88.5%) |  | 33 (76.7%) | 33 (76.7%) |  |
Age (year), Median (range) | 46 (25,70) | 50 (27,67) | 0.1919 | 49 (36–60) | 48 (36–58) | 0.4812 |
Menopausal status, n (%) | Â | Â | 0.1082 | Â | Â | 0.2903 |
 Premenopausal | 38 (58.5%) | 64 (49.2%) |  | 20 (46.5%) | 27 (62.8%) |  |
 Postmenopausal | 22 (33.9%) | 62 (47.7%) |  | 18 (41.9%) | 15 (34.9%) |  |
 Missing | 5 (7.7%) | 4 (3.1%) |  | 5 (11.6%) | 1 (2.3%) |  |
Nodal status, n (%) | Â | Â | 0.0109 | Â | Â | 0.8122 |
 N0 | 22 (33.9%) | 40 (30.8%) |  | 16 (37.2%) | 12 (27.9%) |  |
 N1 | 21 (32.3%) | 25 (19.2%) |  | 14 (32.6%) | 16 (37.2%) |  |
 N2 | 7 (10.8%) | 30 (23.1%) |  | 7 (16.3%) | 9 (20.9%) |  |
 N3 | 7 (10.8%) | 33 (25.4%) |  | 6 (14.0%) | 6 (14.0%) |  |
 Missing | 8 (12.3%) | 2 (1.5%) |  |  |  |  |
Tumor size, n (%) | Â | Â | 0.0452 | Â | Â | 0.9719 |
 T1 | 14 (21.5%) | 43 (33.1%) |  | 14 (32.6%) | 12 (27.9%) |  |
 T2 | 30 (46.2%) | 42 (32.3%) |  | 24 (55.8%) | 26 (60.5%) |  |
 T3 | 4 (6.2%) | 15 (11.5%) |  | 3 (7.0%) | 3 (7.0%) |  |
 T4 | 2 (3.1%) | 13 (10.0%) |  | 2 (4.7%) | 2 (4.7%) |  |
 Missing | 15 (23.1%) | 17 (13.1%) |  |  |  |  |
Molecular subtype, n (%) | Â | Â | 0.5592 | Â | Â | 0.5642 |
 Luminal A | 10 (15.4%) | 18 (13.9%) |  | 8 (18.6%) | 5 (11.6%) |  |
 Luminal B | 30 (46.2%) | 56 (43.1%) |  | 23 (53.5%) | 20 (46.5%) |  |
 HER2+ | 6 (9.2%) | 13 (10.0%) |  | 4 (9.3%) | 2(4.7%) |  |
 BASAL-LIKE | 3 (4.6%) | 14 (10.8%) |  | 1 (2.3%) | 3 (7.0%) |  |
 Missing | 16 (24.6%) | 29 (22.3%) |  | 7 (16.3%) | 13 (30.2%) |  |
Ki-67 expression, n (%) | Â | Â | 0.5803 | Â | Â | 0.7468 |
  < 20% | 8 (12.3%) | 16 (12.3%) |  | 7 (16.3%) | 7 (16.3%) |  |
  ≥ 20% | 34 (52.3%) | 52 (40.0%) |  | 22 (51.2%) | 18 (41.9%) |  |
 Missing | 23 (35.4%) | 62 (47.7%) |  | 14 (32.6%) | 18 (41.9%) |  |